Xvivo Perfusion AB (XVIVO) - Cash Flow Conversion Efficiency

Latest as of March 2026: 0.030x

Based on the latest financial reports, Xvivo Perfusion AB (XVIVO) has a cash flow conversion efficiency ratio of 0.030x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr65.34 Million ≈ $7.03 Million USD) by net assets (Skr2.17 Billion ≈ $233.46 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See net asset quality index of Xvivo Perfusion AB to measure how much of total assets are equity-financed.

Xvivo Perfusion AB - Cash Flow Conversion Efficiency Trend (2011–2025)

This chart illustrates how Xvivo Perfusion AB's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Xvivo Perfusion AB (XVIVO) cash earnings ratio to evaluate the quality of earnings relative to operating cash generation.

Xvivo Perfusion AB Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Xvivo Perfusion AB ranked by their cash flow conversion efficiency.

Company	Cash Flow Conversion Efficiency
GrocerIQ, Inc NYSE:WPFHD	N/A
Beijing Oriental Jicheng Co Ltd SHE:002819	0.017x
Domino's Pizza Enterprises Limited F:HQX	0.082x
IRB-Brasil Resseguros S.A. SA:IRBR3	0.015x
Cullinan Oncology LLC NASDAQ:CGEM	-0.126x
Hna-Caissa Travel Group Co Ltd SHE:000796	-0.094x
Elevra Lithium Limited AU:ELV	-0.051x
Guangzhou Hengyun Enterprises Holding Ltd SHE:000531	0.058x

Annual Cash Flow Conversion Efficiency for Xvivo Perfusion AB (2011–2025)

The table below shows the annual cash flow conversion efficiency of Xvivo Perfusion AB from 2011 to 2025. For the full company profile with market capitalisation and key ratios, see Xvivo Perfusion AB market cap and net worth.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2025-12-31	Skr2.11 Billion ≈ $227.44 Million	Skr101.07 Million ≈ $10.88 Million	0.048x	-7.33%
2024-12-31	Skr2.16 Billion ≈ $232.10 Million	Skr111.29 Million ≈ $11.98 Million	0.052x	+116.83%
2023-12-31	Skr1.95 Billion ≈ $209.32 Million	Skr46.29 Million ≈ $4.98 Million	0.024x	+22.18%
2022-12-31	Skr1.43 Billion ≈ $153.91 Million	Skr27.86 Million ≈ $3.00 Million	0.019x	+307.63%
2021-12-31	Skr1.29 Billion ≈ $138.33 Million	Skr-12.06 Million ≈ $-1.30 Million	-0.009x	+22.87%
2020-12-31	Skr1.01 Billion ≈ $108.53 Million	Skr-12.27 Million ≈ $-1.32 Million	-0.012x	-123.81%
2019-12-31	Skr577.52 Million ≈ $62.15 Million	Skr29.50 Million ≈ $3.18 Million	0.051x	+16.87%
2018-12-31	Skr540.48 Million ≈ $58.16 Million	Skr23.63 Million ≈ $2.54 Million	0.044x	-0.64%
2017-12-31	Skr504.33 Million ≈ $54.27 Million	Skr22.19 Million ≈ $2.39 Million	0.044x	+10.93%
2016-12-31	Skr316.41 Million ≈ $34.05 Million	Skr12.55 Million ≈ $1.35 Million	0.040x	-14.52%
2015-12-31	Skr184.87 Million ≈ $19.90 Million	Skr8.58 Million ≈ $923.13K	0.046x	+318.52%
2014-12-31	Skr176.18 Million ≈ $18.96 Million	Skr-3.74 Million ≈ $-402.59K	-0.021x	-115.24%
2013-12-31	Skr96.64 Million ≈ $10.40 Million	Skr13.46 Million ≈ $1.45 Million	0.139x	+641.01%
2012-12-31	Skr88.77 Million ≈ $9.55 Million	Skr1.67 Million ≈ $179.61K	0.019x	-98.42%
2011-12-31	Skr11.91 Million ≈ $1.28 Million	Skr14.17 Million ≈ $1.52 Million	1.190x	--

About Xvivo Perfusion AB

ST:XVIVO Sweden Medical Devices

Market Cap

$894.24 Million

Skr8.31 Billion SEK

Market Cap Rank

#9226 Global

#146 in Sweden

Share Price

Skr263.80

Change (1 day)

+1.15%

52-Week Range

Skr160.80 - Skr305.20

All Time High

Skr539.00